Francis V Chisari

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4708990/publications.pdf

Version: 2024-02-01

36,446	91	160
citations	h-index	g-index
169	169	28634
docs citations	times ranked	citing authors
	citations 169	36,446 91 citations h-index 169 169

#	Article	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	4.3	3,122
2	Robust hepatitis C virus infection in vitro. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9294-9299.	3. 3	1,597
3	Hepatitis B Virus Immunopathogenesis. Annual Review of Immunology, 1995, 13, 29-60.	9.5	1,550
4	Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection. Science, 1999, 284, 825-829.	6.0	1,144
5	Determinants of Viral Clearance and Persistence during Acute Hepatitis C Virus Infection. Journal of Experimental Medicine, 2001, 194, 1395-1406.	4.2	1,091
6	Intracellular Inactivation of the Hepatitis B Virus by Cytotoxic T Lymphocytes. Immunity, 1996, 4, 25-36.	6.6	1,065
7	NONCYTOLYTICCONTROL OFVIRALINFECTIONS BY THEINNATE ANDADAPTIVEIMMUNERESPONSE. Annual Review of Immunology, 2001, 19, 65-91.	9.5	896
8	CD8 + T Cells Mediate Viral Clearance and Disease Pathogenesis during Acute Hepatitis B Virus Infection. Journal of Virology, 2003, 77, 68-76.	1.5	879
9	Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature, 2007, 449, 919-922.	13.7	827
10	The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T–lymphocyte response. Nature Medicine, 1996, 2, 1104-1108.	15.2	804
11	Nonlinear partial differential equations and applications: Genomic analysis of the host response to hepatitis C virus infection. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 15669-15674.	3.3	796
12	Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell, 1989, 59, 1145-1156.	13.5	701
13	IMMUNOBIOLOGY AND PATHOGENESIS OF VIRAL HEPATITIS. Annual Review of Pathology: Mechanisms of Disease, 2006, 1, 23-61.	9.6	669
14	Genomic analysis of the host response to hepatitis B virus infection. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 6669-6674.	3.3	598
15	Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 15661-15668.	3.3	581
16	Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature, 1994, 369, 407-410.	13.7	572
17	Natural Killer T Cell Activation Inhibits Hepatitis B Virus Replication in Vivo. Journal of Experimental Medicine, 2000, 192, 921-930.	4.2	560
18	Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nature Medicine, 2008, 14, 25-27.	15.2	556

#	Article	IF	CITATIONS
19	Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2561-2566.	3.3	460
20	The autophagy machinery is required to initiate hepatitis C virus replication. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 14046-14051.	3.3	418
21	Short-Range Exosomal Transfer of Viral RNA from Infected Cells to Plasmacytoid Dendritic Cells Triggers Innate Immunity. Cell Host and Microbe, 2012, 12, 558-570.	5.1	413
22	Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence. Hepatology, 1999, 30, 595-601.	3.6	412
23	Stealth and Cunning: Hepatitis B and Hepatitis C Viruses. Journal of Virology, 2005, 79, 9369-9380.	1.5	407
24	Lambda Interferon Inhibits Hepatitis B and C Virus Replication. Journal of Virology, 2005, 79, 3851-3854.	1.5	402
25	Cellular Determinants of Hepatitis C Virus Assembly, Maturation, Degradation, and Secretion. Journal of Virology, 2008, 82, 2120-2129.	1.5	398
26	Toll-Like Receptor Signaling Inhibits Hepatitis B Virus Replication In Vivo. Journal of Virology, 2005, 79, 7269-7272.	1.5	395
27	Interference of hepatitis C virus RNA replication by short interfering RNAs. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2014-2018.	3.3	369
28	Immune Pathogenesis of Hepatocellular Carcinoma. Journal of Experimental Medicine, 1998, 188, 341-350.	4.2	354
29	Hydrodynamic injection of viral DNA: A mouse model of acute hepatitis B virus infection. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13825-13830.	3.3	353
30	A global scientific strategy to cure hepatitis B. The Lancet Gastroenterology and Hepatology, 2019, 4, 545-558.	3.7	342
31	Differential CD4+ and CD8+ T-cell responsiveness in hepatitis C virus infection. Hepatology, 2001, 33, 267-276.	3. 6	316
32	Platelets mediate cytotoxic T lymphocyte–induced liver damage. Nature Medicine, 2005, 11, 1167-1169.	15.2	311
33	Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. Journal of Clinical Investigation, 2010, 120, 924-930.	3.9	305
34	The Size of the Viral Inoculum Contributes to the Outcome of Hepatitis B Virus Infection. Journal of Virology, 2009, 83, 9652-9662.	1.5	282
35	Viruses, Immunity, and Cancer: Lessons from Hepatitis B. American Journal of Pathology, 2000, 156, 1117-1132.	1.9	279
36	Immunosurveillance of the Liver by Intravascular Effector CD8 + T Cells. Cell, 2015, 161, 486-500.	13.5	271

#	Article	IF	CITATIONS
37	Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2165-72.	3.3	267
38	To kill or to cure: options in host defense against viral infection. Current Opinion in Immunology, 1996, 8, 478-483.	2.4	257
39	Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics, 2005, 57, 304-314.	1.2	255
40	Plasmacytoid dendritic cells sense hepatitis C virus–infected cells, produce interferon, and inhibit infection. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7431-7436.	3.3	239
41	Relative Sensitivity of Hepatitis B Virus and Other Hepatotropic Viruses to the Antiviral Effects of Cytokines. Journal of Virology, 2000, 74, 2255-2264.	1.5	238
42	Initiation of Hepatitis C Virus Infection Is Dependent on Cholesterol and Cooperativity between CD81 and Scavenger Receptor B Type I. Journal of Virology, 2007, 81, 374-383.	1.5	234
43	Persistent Hepatitis C Virus Infection In Vitro: Coevolution of Virus andHost. Journal of Virology, 2006, 80, 11082-11093.	1.5	228
44	Intrahepatic Induction of Alpha/Beta Interferon Eliminates Viral RNA-Containing Capsids in Hepatitis B Virus Transgenic Mice. Journal of Virology, 2000, 74, 4165-4173.	1.5	226
45	Blocking Chemokine Responsive to γ–2/Interferon (IFN)-γ Inducible Protein and Monokine Induced by IFN-γ Activity In Vivo Reduces the Pathogenetic but not the Antiviral Potential of Hepatitis B Virus–specific Cytotoxic T Lymphocytes. Journal of Experimental Medicine, 2001, 194, 1755-1766.	4.2	225
46	A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 14913-14918.	3.3	219
47	Differential Biophysical Properties of Infectious Intracellular and Secreted Hepatitis C Virus Particles. Journal of Virology, 2006, 80, 11074-11081.	1.5	214
48	PD-1:PD-L1 Interactions Contribute to the Functional Suppression of Virus-Specific CD8+ T Lymphocytes in the Liver. Journal of Immunology, 2007, 178, 2714-2720.	0.4	214
49	Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 773-778.	3.3	212
50	Hepatitis C Virus Blocks Interferon Effector Function by Inducing Protein Kinase R Phosphorylation. Cell Host and Microbe, 2009, 6, 513-522.	5.1	206
51	Immune effectors required for hepatitis B virus clearance. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 798-802.	3.3	206
52	Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 2129-2134.	3.3	202
53	Unscrambling hepatitis C virus–host interactions. Nature, 2005, 436, 930-932.	13.7	198
54	Immune Tolerance Split between Hepatitis B Virus Precore and Core Proteins. Journal of Virology, 2005, 79, 3016-3027.	1.5	194

#	Article	IF	CITATIONS
55	Gene expression during the priming phase of liver regeneration after partial hepatectomy in mice. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11181-11186.	3.3	183
56	Ultrastructural and Biophysical Characterization of Hepatitis C Virus Particles Produced in Cell Culture. Journal of Virology, 2010, 84, 10999-11009.	1.5	178
57	Oscillating CD8+ T Cell Effector Functions after Antigen Recognition in the Liver. Immunity, 2005, 23, 53-63.	6.6	174
58	Viruses and the autophagy machinery. Cell Cycle, 2010, 9, 1295-1307.	1.3	169
59	Interleukin-18 Inhibits Hepatitis B Virus Replication in the Livers of Transgenic Mice. Journal of Virology, 2002, 76, 10702-10707.	1.5	166
60	Hepatitis B virus transgenic mice: Insights into the virus and the disease*1. Hepatology, 1995, 22, 1316-1325.	3.6	164
61	Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. Hepatology, 2014, 59, 2121-2130.	3.6	162
62	Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9913-9917.	3.3	155
63	Double-stranded DNA and double-stranded RNA induce a common antiviral signaling pathway in human cells. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 9035-9040.	3.3	146
64	HBsAg retention sensitizes the hepatocyte to injury by physiological concentrations of interferon- \hat{l}^3 . Hepatology, 1992, 16, 655-663.	3.6	144
65	Immunology and the liver. Hepatology, 1991, 13, 977-994.	3.6	141
66	Dynamics of hepatitis B virus clearance in chimpanzees. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 17780-17785.	3.3	140
67	Native Hepatitis B Virions and Capsids Visualized by Electron Cryomicroscopy. Molecular Cell, 2006, 22, 843-850.	4.5	139
68	Inhibition of Hepatitis B Virus Replication during Adenovirus and Cytomegalovirus Infections in Transgenic Mice. Journal of Virology, 1998, 72, 2630-2637.	1.5	138
69	Host–virus interactions in hepatitis B virus infection. Current Opinion in Immunology, 2015, 36, 61-66.	2.4	133
70	A virocidal amphipathic α-helical peptide that inhibits hepatitis C virus infection <i>in vitro</i> . Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3088-3093.	3.3	129
71	Behçet's disease. Survey of Ophthalmology, 1982, 26, 190-203.	1.7	127
72	Hepatitis B virus transgenic mice: Insights into the virus and the disease. Hepatology, 1995, 22, 1316-1325.	3.6	127

#	Article	IF	CITATIONS
73	Immunogenicity and Tolerogenicity of Hepatitis B Virus Structural and Nonstructural Proteins: Implications for Immunotherapy of Persistent Viral Infections. Journal of Virology, 2002, 76, 8609-8620.	1.5	127
74	CD40 Activation Rescues Antiviral CD8+ T Cells from PD-1-Mediated Exhaustion. PLoS Pathogens, 2013, 9, e1003490.	2.1	127
75	Cytokine-Mediated Control of Viral Infections. Virology, 2000, 273, 221-227.	1.1	123
76	Hepatitis B virus immunopathology. Seminars in Immunopathology, 1995, 17, 261-81.	4.0	120
77	Cytokine-Sensitive Replication of Hepatitis B Virus in Immortalized Mouse Hepatocyte Cultures. Journal of Virology, 2002, 76, 5646-5653.	1.5	119
78	Platelets prevent IFN- \hat{l} ± \hat{l}^2 -induced lethal hemorrhage promoting CTL-dependent clearance of lymphocytic choriomeningitis virus. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 629-634.	3.3	119
79	Nitric Oxide Inhibits Hepatitis B Virus Replication in the Livers of Transgenic Mice. Journal of Experimental Medicine, 2000, 191, 1247-1252.	4.2	117
80	The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunologic Research, 1998, 18, 79-92.	1.3	115
81	Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease-dependent and -independent mechanisms. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 8499-8504.	3 . 3	113
82	Interferon-Regulated Pathways That Control Hepatitis B Virus Replication in Transgenic Mice. Journal of Virology, 2002, 76, 2617-2621.	1.5	112
83	Depletion of neutrophils blocks the recruitment of antigen-nonspecific cells into the liver without affecting the antiviral activity of hepatitis B virus-specific cytotoxic T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13717-13722.	3.3	110
84	Activated Intrahepatic Antigen-Presenting Cells Inhibit Hepatitis B Virus Replication in the Liver of Transgenic Mice. Journal of Immunology, 2002, 169, 5188-5195.	0.4	109
85	Searching for Interferon-Induced Genes That Inhibit Hepatitis B Virus Replication in Transgenic Mouse Hepatocytes. Journal of Virology, 2003, 77, 1227-1236.	1.5	108
86	MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. Journal of Clinical Investigation, 2004, 113, 1158-1167.	3.9	106
87	Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice. Hepatology, 1995, 21, 620-626.	3.6	105
88	Hepatitis C Virus (HCV) Induces Formation of Stress Granules Whose Proteins Regulate HCV RNA Replication and Virus Assembly and Egress. Journal of Virology, 2012, 86, 11043-11056.	1.5	104
89	Cutting Edge: Inhibition of Hepatitis B Virus Replication by Activated NK T Cells Does Not Require Inflammatory Cell Recruitment to the Liver. Journal of Immunology, 2001, 167, 6701-6705.	0.4	102
90	Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 291-296.	3.3	101

#	Article	IF	CITATIONS
91	Virion-Independent Transfer of Replication-Competent Hepatitis C Virus RNA between Permissive Cells. Journal of Virology, 2015, 89, 2956-2961.	1.5	100
92	Kupffer Cells Hasten Resolution of Liver Immunopathology in Mouse Models of Viral Hepatitis. PLoS Pathogens, 2011, 7, e1002061.	2.1	96
93	Induction of specific cytochrome P450s involved in aflatoxin B1 metabolism in hepatitis B virus transgenic mice. Molecular Carcinogenesis, 1994, 11, 74-80.	1.3	94
94	Production of Infectious Hepatitis C Virus by Well-Differentiated, Growth-Arrested Human Hepatoma-Derived Cells. Journal of Virology, 2006, 80, 10253-10257.	1.5	92
95	Hepatitis B Virus RNA-Binding Proteins Associated with Cytokine-Induced Clearance of Viral RNA from the Liver of Transgenic Mice. Journal of Virology, 1999, 73, 474-481.	1.5	91
96	Hepatitis B small surface antigen particles are octahedral. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14783-14788.	3.3	90
97	Human Transporters Associated with Antigen Processing (Taps) Select Epitope Precursor Peptides for Processing in the Endoplasmic Reticulum and Presentation to T Cells. Journal of Experimental Medicine, 1999, 190, 1227-1240.	4.2	86
98	Replication of a hepatitis C virus replicon clone in mouse cells. Virology Journal, 2006, 3, 89.	1.4	85
99	Previously Infected Chimpanzees Are Not Consistently Protected against Reinfection or Persistent Infection after Reexposure to the Identical Hepatitis C Virus Strain. Journal of Virology, 2008, 82, 8183-8195.	1.5	81
100	Recombinant Duck Interferon Gamma Inhibits Duck Hepatitis B Virus Replication in Primary Hepatocytes. Journal of Virology, 1999, 73, 3162-3168.	1.5	80
101	La Autoantigen Specifically Recognizes a Predicted Stem-Loop in Hepatitis B Virus RNA. Journal of Virology, 1999, 73, 5767-5776.	1.5	79
102	Hepatitis B virus structure and biology. Microbial Pathogenesis, 1989, 6, 311-325.	1.3	78
103	Inhibition of Hepatitis B Virus Replication by Interferon Requires Proteasome Activityâ€. Journal of Virology, 2002, 76, 3570-3574.	1.5	77
104	Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5525-5530.	3.3	75
105	Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome. International Immunology, 1996, 8, 651-659.	1.8	74
106	Signal transduction pathways that inhibit hepatitis B virus replication. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1743-1747.	3.3	74
107	Cytokine-induced viral purging â€" role in viral pathogenesis. Current Opinion in Microbiology, 1999, 2, 388-391.	2.3	73
108	Overcoming T Cell Tolerance to the Hepatitis B Virus Surface Antigen in Hepatitis B Virus-Transgenic Mice. Journal of Immunology, 2001, 166, 1389-1397.	0.4	73

#	Article	IF	Citations
109	Transcriptional and posttranscriptional control of hepatitis B virus gene expression. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 1310-1315.	3.3	71
110	Immunopathology of hepatitis C. Seminars in Immunopathology, 1997, 19, 57-68.	4.0	70
111	Protein transfer of preformed MHC-peptide complexes sensitizes target cells to T cell cytolysis. Immunity, 1994, 1, 607-613.	6.6	65
112	MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. Journal of Clinical Investigation, 2004, 113, 1158-1167.	3.9	63
113	Hepatic preneoplasia in hepatitis B virus transgenic mice. Hepatology, 1994, 20, 1162-1172.	3.6	62
114	Host–Virus Interactions during Malaria Infection in Hepatitis B Virus Transgenic Mice. Journal of Experimental Medicine, 2000, 192, 529-536.	4.2	61
115	Autophagy proteins promote hepatitis C virus replication. Autophagy, 2009, 5, 1224-1225.	4.3	58
116	Elimination of Duck Hepatitis B Virus RNA-Containing Capsids in Duck Interferon-Alpha-Treated Hepatocytes. Journal of Virology, 1999, 73, 5459-5465.	1.5	54
117	Immunological Aspects of HCV Infection. Intervirology, 1994, 37, 119-125.	1.2	53
118	Characterization of Nuclear RNases That Cleave Hepatitis B Virus RNA near the La Protein Binding Site. Journal of Virology, 2001, 75, 6874-6883.	1.5	53
119	Inductionin vitro of a primary human antiviral cytotoxic T cell response. European Journal of Immunology, 1995, 25, 627-630.	1.6	51
120	Effector CD8+ T cell-derived interleukin-10 enhances acute liver immunopathology. Journal of Hepatology, 2017, 67, 543-548.	1.8	48
121	In Vivo Study of the HC-TN Strain of Hepatitis C Virus Recovered from a Patient with Fulminant Hepatitis: RNA Transcripts of a Molecular Clone (pHC-TN) Are Infectious in Chimpanzees but Not in Huh7.5 Cells. Journal of Virology, 2007, 81, 7208-7219.	1.5	47
122	Impact of the Autophagy Machinery on Hepatitis C Virus Infection. Viruses, 2011, 3, 1342-1357.	1.5	46
123	Self-Assembling Peptide Nanotubes with Antiviral Activity against Hepatitis C Virus. Chemistry and Biology, 2011, 18, 1453-1462.	6.2	44
124	Sigma-1 Receptor Regulates Early Steps of Viral RNA Replication at the Onset of Hepatitis C Virus Infection. Journal of Virology, 2013, 87, 6377-6390.	1.5	44
125	Role of Immunoproteasome Catalytic Subunits in the Immune Response to Hepatitis B Virus. Journal of Virology, 2007, 81, 483-491.	1.5	42
126	Inhibition of Hepatitis B Virus Replication during Schistosoma mansoni Infection in Transgenic Mice. Journal of Experimental Medicine, 2000, 192, 289-294.	4.2	39

#	Article	IF	CITATIONS
127	Ongoing Murine T1 or T2 Immune Responses to the Hepatitis B Surface Antigen Are Excluded from the Liver that Expresses Transgene-Encoded Hepatitis B Surface Antigen. Journal of Immunology, 2000, 164, 4235-4243.	0.4	38
128	Targeting Murine Immune Responses to Selected T Cell- or Antibody-Defined Determinants of the Hepatitis B Surface Antigen by Plasmid DNA Vaccines Encoding Chimeric Antigen. Journal of Immunology, 2001, 166, 1405-1413.	0.4	38
129	In vitro induction of primary, antigen-specific CTL from human peripheral blood mononuclear cells stimulated with synthetic peptides. Molecular Immunology, 1995, 32, 603-612.	1.0	33
130	Comment on "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA― Science, 2014, 344, 1237-1237.	6.0	33
131	Pathogenic Role of B Cells in Anti-CD40-Induced Necroinflammatory Liver Disease. American Journal of Pathology, 2006, 168, 786-795.	1.9	32
132	Serum HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV infection. Journal of Experimental Medicine, 2020, 217, .	4.2	31
133	Hepatitis B Virus Biology and Pathogenesis. , 1992, 2, 67-104.		31
134	Identification of Five Different Patr Class I Molecules That Bind HLA Supertype Peptides and Definition of Their Peptide Binding Motifs. Journal of Immunology, 2000, 165, 4414-4422.	0.4	30
135	Degenerate Immunogenicity of an HLA-A2-Restricted Hepatitis B Virus Nucleocapsid Cytotoxic T-Lymphocyte Epitope That Is Also Presented by HLA-B51. Journal of Virology, 2001, 75, 3984-3987.	1.5	30
136	Recognition of a novel naturally processed, A2 restricted, HCV-NS4 epitope triggers IFN-gamma release in absence of detectable cytopathicity. Human Immunology, 1998, 59, 776-782.	1.2	27
137	Differential dynamics of the peripheral and intrahepatic cytotoxic T lymphocyte response to hepatitis B surface antigen. Virology, 2005, 333, 293-300.	1.1	27
138	Repression of hepatitis B virus (HBV) transgene and HBV-induced liver injury by low protein diet. Oncogene, 1997, 15, 2795-2801.	2.6	26
139	Theimunopathogenesis of cronic HBV inducedliver disease. Seminars in Immunopathology, 1981, 3, 439-459.	4.0	25
140	Detailed characterization of the peptide binding specificity of five common Patr class I MHC molecules. Immunogenetics, 2006, 58, 559-570.	1.2	25
141	Subretinal Neovascular Membrane and Disciform Scar in Behçet's Disease. American Journal of Ophthalmology, 1980, 90, 182-185.	1.7	23
142	Bortezomib Inhibits Hepatitis B Virus Replication in Transgenic Mice. Antimicrobial Agents and Chemotherapy, 2010, 54, 749-756.	1.4	23
143	Production of two distinct and independent hepatic immunoregulatory molecules by the perfused rat liver. Hepatology, 1985, 5, 735-743.	3 . 6	22
144	GB Virus C and Mortality from HIV Infection. New England Journal of Medicine, 2002, 346, 377-379.	13.9	20

#	Article	IF	Citations
145	Characterization of the peptide-binding specificity of the chimpanzee class I alleles A*0301 and A*0401 using a combinatorial peptide library. Immunogenetics, 2007, 59, 745-751.	1.2	20
146	Modulation of the in vivo immune response by human plasma very low-density lipoproteins. Cellular Immunology, 1980, 52, 223-228.	1.4	18
147	Antibodies to Oral Mucosa in Patients with Ocular Behcet's Disease. Ophthalmology, 1985, 92, 1277-1281.	2.5	18
148	Elevations of Hepatic Quinone Reductase, Glutathione, and \hat{l}_{\pm} - and \hat{l}_{4} -Class GlutathioneS-Transferase Isoforms in Mice with Chronic Hepatitis: A Compensatory Response to Injury. Archives of Biochemistry and Biophysics, 1996, 331, 104-116.	1.4	17
149	Intracellular Hepatitis B Virus Nucleocapsids Survive Cytotoxic T-Lymphocyte-Induced Apoptosis. Journal of Virology, 2000, 74, 9792-9796.	1.5	15
150	Antiviral Stilbene 1,2-Diamines Prevent Initiation of Hepatitis C Virus RNA Replication at the Outset of Infection. Journal of Virology, 2011, 85, 5513-5523.	1.5	15
151	Suppression of Lymphocyte Activation by a Protein Released from Isolated Perfused Rat Liver. Hepatology, 1982, 2, 295S-303S.	3.6	14
152	Evaluation of monoclonality of cell lines from sequential dilution assays. Journal of Immunological Methods, 1987, 105, 139-143.	0.6	13
153	IMMUNOPATHOGENESIS OF HEPATITIS B VIRUS INFECTION. Clinics in Liver Disease, 1999, 3, 221-239.	1.0	12
154	Modulation of peripheral blood mononuclear cell cyclic adenosine monophosphate levels by human very low density lipoprotein. Cellular Immunology, 1981, 65, 325-336.	1.4	8
155	Is antigenic variability a strategy adopted by hepatitis B virus to escape cytotoxic T-lymphocyte surveillance?. Seminars in Virology, 1996, 7, 23-30.	4.1	8
156	Use of immunoglobulin light chain analysis to detect bone marrow involvement in B-cell neoplasms. Clinical Immunology and Immunopathology, 1982, 24, 139-144.	2.1	5
157	Hepatic preneoplasia in hepatitis B virus transgenic mice. Hepatology, 1994, 20, 1162-1172.	3.6	5
158	A Proposed Role for the Immune System in the Pathogenesis of Hepatitis B Virus Induced Liver Disease. CRC Critical Reviews in Clinical Laboratory Sciences, 1981, 15, 335-353.	1.0	2
159	Pathogenesis of Hepatitis B Virus inTransgenic Mice. , 2005, 25, 25-32.		1
160	The Role of the Cytotoxic T Lymphocyte Response in Hepatitis B Virus Immunobiology and Pathogenesis. , 1994, , 173-177.		1
161	Protective and Pathogenic T Cell Responses to Virus Infections. , 2016, , 318-323.		1
162	Pioneers of pathogenesis: past and present. Current Opinion in Virology, 2011, 1, 157-159.	2.6	0

#	Article	IF	CITATIONS
163	Role of Fas Ligand in Immunopathogenesis of Hepatocellular Carcinoma. , 2002, , 73-80.		0
164	Platelets Mediate Cytotoxic T Lymphocyte-Induced Liver Damage Blood, 2005, 106, 651-651.	0.6	0
165	Platelets Mediate Clearance of Lymphocytic Choriomeningitis Virus Infection Preventing Lethal Hemorrhage Blood, 2006, 108, 1089-1089.	0.6	O
166	Antibodies to Oral Mucosa in Patients with Ocular Behcet's Disease. Documenta Ophthalmologica Proceedings Series, 1987, , 291-298.	0.0	0